Novo vs. Lilly: Q2's cardiometabolic grudge match
For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of companies are chasing their frontrunner status ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Lilly climbs, Novo falls as obesity drug battle intensifies biopharmadive.com
